key: cord-0966803-xgcnon36
authors: Javanmardi, Kamyab; Segall-Shapiro, Thomas H.; Chou, Chia-Wei; Boutz, Daniel R.; Olsen, Randall J.; Xie, Xuping; Xia, Hongjie; Shi, Pei-Yong; Johnson, Charlie D.; Annapareddy, Ankur; Weaver, Scott; Musser, James M.; Ellington, Andrew D.; Finkelstein, Ilya J.; Gollihar, Jimmy D.
title: Antibody escape and cryptic cross-domain stabilization in the SARS-CoV-2 Omicron spike protein
date: 2022-04-18
journal: bioRxiv
DOI: 10.1101/2022.04.18.488614
sha: 1882b7553b6b83df22295f9daad0725d1cd44d5a
doc_id: 966803
cord_uid: xgcnon36

The worldwide spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to the repeated emergence of variants of concern. The Omicron variant has two dominant sub-lineages, BA.1 and BA.2, each with unprecedented numbers of nonsynonymous and indel spike protein mutations: 33 and 29, respectively. Some of these mutations individually increase transmissibility and enhance immune evasion, but their interactions within the Omicron mutational background is unknown. We characterize the molecular effects of all Omicron spike mutations on expression, human ACE2 receptor affinity, and neutralizing antibody recognition. We show that key mutations enable escape from neutralizing antibodies at a variety of epitopes. Stabilizing mutations in the N-terminal and S2 domains of the spike protein compensate for destabilizing mutations in the receptor binding domain, thereby enabling the record number of mutations in Omicron sub-lineages. Taken together, our results provide a comprehensive account of the mutational effects in the Omicron spike protein and illuminate previously unknown mechanisms of how the N-terminal domain can compensate for destabilizing mutations within the more evolutionarily constrained RBD.

Conversely, binding of class III and IV mAbs was more sensitive to mutations located at the base 153 of the N3-loop (G142D and del142) ( Figure S2I) . Mutations del211 and ins214EPE each decreased binding 154 of mAb 5-7 1.9-fold and moderately decreased pseudovirus neutralization (Figures 2B and S2G ) 21 . These 155 results document the importance of both the G142D substitution and the 143-145 deletion for the ability of 156 BA.1 to escape different classes of NTD-targeting mAbs. 157 BA.2 still retained sensitivity to some NTD-targeting mAbs ( Figure 1F) . Mutations in the N1-loop 158 (T19I, L24R, del25-del27) moderately decreased binding for class II, III, and IV mAbs ( Figure 2C and 159 Figure S2J ) and in combination with G142D, BA.2 completely escaped antibody recognition at this site. 160

Notably, the V213G substitution, found distal from the N-loops and in the same location as the del211, 161 L212I, ins214EPE mutation cluster in BA.1, was inconsequential for mAb binding. However, these 162 mutations may influence virus fitness at the RNA or protein level in ways that cannot be accessed by our for the class II, III, and IV mAbs ( Figure 2G) . Surprisingly, reversion of T19I in the BA.2 context failed 172 to restore any binding for mAb CM30, due to the strong escape elicited by the other BA.2 NTD mutations. Figure 3A) . To study the 183 effects of these RBD substitutions on mAb binding we first screened WHU1 spike protein variants 184 containing each of the individual mutations found in BA.1 and BA.2, using the 12 previously described 185 RBD-targeting mAbs (Figures 3B and S3A ). S2X35, a class I mAb, showed moderately reduced binding 186 due to the E484A mutation. However, each of the S371F, D405N, and R408S AA substitutions caused 187 substantial decreases in binding, likely accounting for the enhanced resistance of BA.2 to mAb S2X35. 188

Class II antibodies C002, C144, and LY-CoV555, and the quaternary binder 2-43, were most affected by 189 the E484A and Q493R single mutations. Class III mAb REGN10987 showed decreased binding with both 190 the N440K and G446S single mutations, and C135 binding was greatly affected by both N440K and Q498R 191 ( Figure 3B) that each break a mAb-spike protein binding interaction. For example, C144 binding was strongly 222 disrupted by either E484A or Q493R when these mutations were made to the WHU1 spike but reverting 223 E484A in the BA.1 or BA.2 spike failed to restore binding ( Figure 3G ). Necessary but not sufficient 224 mutations (above the diagonal line) may indicate mutational clusters that have a synergistic or epistatic 225 effect on antibody binding. As an example, N440K reduced, and G446S and N501Y slightly reduced the 226 binding of antibody C135 when made in the WHU1 context ( Figure 3H ). BA.1, which has these three 227 mutations, nearly eliminated C135 binding, and this binding was partially restored when any of the three 228 mutations are reverted. The restoration effect from BA.1 is considerably larger than the reduction in 229 binding from WHU1 suggesting that N440K, G446S, and N501Y have synergistic effects greater than 230 their individual effects. In contrast, BA.2, which lacks G446S, does not show such clear synergy between 231 N440K and N501Y. Overall, these results highlight antigenic differences between the BA.1 and BA.2 232 spike RBDs and how the overall genetic context impacts antibody escape ( Figure S3C) . We screened each single RBD amino acid substitution in the WHU1 spike protein and observed increased 237 hACE2 binding with the S477N and N501Y mutations ( Figure 3I) . Conversely, mutations S371F, S375F, 238 G496S, and Y505H decreased hACE2 affinity. These results are consistent with previously reported RBD 239 DMS measurements 51 , although S371F was more detrimental to hACE2 binding in our assay. We speculate 240 this is due to contextual effects of the full spike glycoprotein. 241

Reverting each individual RBD mutation in the BA.1 and BA.2 spike proteins showed the 242 deleterious effects of S371F, S375F, K417N, Q496S, and Y505H on hACE2 binding to be less severe in 243 the Omicron contexts. The critical role of N501Y for hACE2 binding by the BA.1 and BA.2 spikes was 244 also shown, as its removal nearly abrogated hACE2 binding, in our assays (Figures 3I and S3D-E) . 245

Although Q498R mildly reduced hACE2 binding in the WHU1 context, it improved hACE2 binding for 246 the BA.1 spike, and, to a lesser extent the BA.2 spike. Cooperative hACE2 binding due to the Q498R and 247 N501Y substitutions has been previously noted, but to our knowledge the mutation-specific effects had not 248 been measured in the full BA.1 and BA.2 spike proteins 50,52 . We validated these results via biolayer 249 interferometry (BLI). Using dimeric hACE2 we see similar changes in binding (Figures 3J and S3H) . (Figures S3F-G) . These mAbs simultaneously engage 256 two or three RBDs to enhance their binding via avidity effects. We reasoned that these antibodies can't 257

bind Omicron relative to the WHU1 spike because of subtle changes in the RBD conformation dynamics. Mutations N440K and E484A, which are responsible for mAb escape, and N501Y, which enhances hACE2 293 affinity are also mildly destabilizing ( Figure S4D) . 294

Next, we assayed each set of domain-specific mutations (NTD, RBD, and S2) in the context of 295 WHU1 spike ( Figure 4F ) to determine their relative effects on spike expression. We found that both the 296 BA.1-and BA.2-RBD mutation sets greatly reduced spike protein expression relative to WHU1, whereas 297 the NTD and S2 mutation sets increased expression. The fully mutated BA.1 spike had greater expression 298 than the WHU1 spike, suggesting that the destabilizing mutations in the RBD are compensated for primarily To test how expression relates to spike stability, we tested the thermal denaturation of a subset of spike 309 variants via differential scanning fluorimetry (DSF) (see Methods). Soluble SARS-CoV-2 spike trimers 310 generate two distinct denaturation peaks, denoted here as Tm1 and Tm2. Compared to other VOCs, the 311 BA.1 and BA.2 spike proteins have poor thermostability, as shown by their respective 7 °C and 6 °C shifts 312 in Tm1, relative to WHU1 (Figures S4A-B) . DSF measurements of spike variants reveals that these effects 313 are driven by RBD mutations in BA.1 (Figures S4C-F Omicron spike proteins, suggesting redundant mutations contributing to antigenic escape (Figure 3B-D) . generally failed to restore binding for the four mAbs we tested that were capable of binding multiple RBDs 343 at once: C002, C144, 2-43, and N3-1 (Figures S3F-G) . These results suggested that the virus was likely 344 not simply presenting different epitopes than the ancestral variant but presenting them in the context of 345 different proportions of RBD up vs down states. We showed that RBD-S2 cross-domain interactions in the 346 BA.1 spike led to reduced N3-1 binding beyond the BA.1-RBD mutations alone (Figure 4C) . In further 347 support of this hypothesis, the removal of the N856K and L981F mutations from the BA.1 spike, which are 348 implicated in creating cross-domain interactions, partially restored N3-1 binding to the level of the BA.1-349 RBD mutations alone (Figure 4D) . Similarly, BA.2-RBD mutations proved even more effective than BA.1-RBD mutations for escaping N3-1, in line with recently solved structures that show that the down 351 conformation of the RBD is largely stabilized in the BA.2-RBD mutations 58 . 352

The accumulation of novel mutation clusters in Omicron, likely due to selection pressure to evade 353 immunity, came at the cost of destabilizing the RBD. Several RBD mutations, most notably S375F, 354 drastically reduce spike expression (Figure S4D) . We propose that NTD mutations such as the 69-70 355 deletion offset protein folding/stability deficiencies associated with Omicron RBDs 57 . Addition of BA.1-356 NTD mutations compensated for the poor expression of the BA.1-RBD mutations (Figure 4F) . 357

Interestingly, the same compensation effects were not seen with the BA.2-NTD and BA.2-RBD mutations, 358 resulting a lower net expression of BA.2 spike relative to WHU1 in our assays. Future studies will be 359 required to explore whether and how improvements in immune evasion have led to fitness costs for Omicron 360 relative to spike expression and fitness. 361

Our data suggest that the Omicron BA.1 and BA.2 subvariants retain high affinity for hACE2. 362

Previous directed evolution 52 and YSD-DMS 50 studies have shown N501Y to greatly improve hACE2 363 binding and Q498R to moderately reduce it; these studies also determined that the co-occurrence of N501Y 364 and Q498R synergistically boosted hACE2 affinity. We confirm that the full Omicron BA.1 and BA.2 365 spikes also benefit from these substitutions, with N501Y and Q498R playing critical roles in the molecular 366 engagement of hACE2 (Figure 3I-J) . Intriguingly, this effect appears distinct in BA.1 versus BA.2 ( Figure  367 S3D-E). As compared to BA.1, N501Y has a much greater impact on ACE2 binding in BA.2 but Q498R is 368 not as critical, possibly due to the absence of BA.1 mutations G446S and G496S. Taken together, these 369 results reveal evolutionary features of Omicron spikes that enable the accruement of immune evasive 370 mutations without sacrificing hACE2 affinity and infectivity. 371

Our study has several limitations. First, we used a prefusion stabilized spike protein that does not 372 precisely mimic the dynamics of the native Omicron spike protein 26 . Second, our binding assays use a set 373 of potent neutralizing mAbs which only serve as proxies for the antibodies found in patient antibody 374 repertoires after immunization or natural infection. Third, our work only touches on antibody recognition 375 and hACE2 binding; T-cell immunity plays a critical role in protecting against SARS-CoV-2 disease. 376

Additional studies focused on the perturbations of spike variants on T-cell response will continue to bridge 377 the gap in the understanding of immune escape between humoral and cell-mediated immunity. 378

In the aggregate, the data presented here add critical new information about key features of 379

Omicron spike protein mutations and how these mutations synergize to create spike variants that 380 successfully evade antibodies while maintaining high affinity hACE2 binding. Our binding maps largely 381 complement prior structure-based studies of binding escape, but now provide new insights into the role of 382 compensatory substitutions in the NTD that impact both expression/stability and conformation. We 383 conclude that the continuing accumulation of NTD mutations will further alter the conformational 384 equilibrium and stability of the spike protein to allow for the accumulation of new, more virulent 385 mutations in the RBD. Further, our study also highlights the importance of rapidly analyzing novel 386 variant spike proteins in near-native contexts. As SARS-CoV-2 continues to evolve and new variants 387 inevitably arise and spread, it is critical that these mutations can be understood in their native genetic 388 contexts to better inform future therapeutic targets and vaccine formulations. Finally, the strategy we have 389 used here will be applicable to future zoonotic outbreaks and other heretofore unrelated microbial 390 pathogens. Mammalian cell-display will continue to serve as a powerful platform for investigating 391 evolutionary trajectories of infectious agents and engineering conformational vaccine candidates. in Figure S1E .

H. Authentic BA.1 virus neutralization for selected RBD-directed monoclonal antibodies as in Figure  417 1G. 418 Figure 2F . 435

For all plots, mean ± SD of log-transformed values from at least two biological replicates D. Additional N3-1 binding data as in Figure 4C . 

One or more of the authors of this paper self-identifies as an underrepresented ethnic minority in science.

The author list of this paper includes contributors from the location where the research was conducted 532 who participated in the data collection, design, analysis, and/or interpretation of the work. (NEB B0202A), and nuclease-free water to bring the final volume to 10 µL per reaction. We incubated 549

the reaction mixtures on a thermocycler using the following settings: 25 digestion and ligation cycles (1 550 min at 37°C and 2 min at 16°C), a final digestion step (30 min at 37°C), and heat inactivation (20 min at 551 80°C). For assemblies with 4+ parts, we increased the cycled digestion and ligation steps to 3 and 5 min, 552

respectively, to improve assembly efficiencies. 553

We transformed each unique reaction mixture into NEB10-beta cells (NEB, C3019) using the 554

Mix & Go! E.coli Transformation Buffer Set (Zymo Research, T3002). Cell were outgrown with SOC at 555

37°C and drop-plated onto LB agar + carbenicillin in Nunc OmniTrays (5 μL per spot, 96-spots per plate) 556

(Thermo Fisher, 140156). We allowed the drops to dry at room temperature before transferring the plates 557

to an incubator at 37°C for growth overnight. After growth, we picked colonies into deep well grow 558 blocks (Axygen P-2ML-SQ-C-S or Greiner Bio-One, 780270) containing 1 mL of Superior Broth 559 (AthenaES, 0105) media + carbenicillin and grew them overnight at 37°C with shaking. Overnights were 560 miniprepped using the Wizard SV 96 Plasmid DNA Purification Kit (Promega A2250) and sequence-561

verified before further characterization.

Expression and purification of neutralizing anti-spike monoclonal antibodies 564 We cultured Expi293 cells in Expi293 Expression Medium (Sigma-Aldrich A1435101) and used a 565 humidified cell culture incubator to maintain cells at 37°C and 8% CO2 with continuous shaking at 125 566 rpm. For transfection, we used an Expi293 Transfection Kit (Sigma-Aldrich L3287) according to the 567 manufacturer's instructions. Briefly, we transfected cells with VH and VL expression vectors at a 1:3 568 molar ratio. Five days after transfection, we collected the protein-containing supernatant using a two-step 569 centrifugation protocol. First, we separated cells and supernatant by centrifuging cultures at 4°C and 300 570 g for 5 min. Next, we separated cell debris and supernatant by centrifuging at 4°C and 3,000 g for 25 min. 571

To purify human IgGs, we washed Protein G magnetic beads (Promega G7471) with PBS buffer and 572

added the beads to the separated supernatant in a 1:10 volumetric ratio. After a 1h incubation with 573 gyration at room temperature, we used a magnetic peg stand to pellet bead-bound antibodies, which we 574 washed before final elution with a 100 mM glycine-HCl solution at pH 2.5. Finally, we passed the elute 575 through a 0.22-μm syringe filter to clarify residual beads before neutralization with 2 M Tris buffer at pH 576 7.5. We kept purified antibodies at 4°C or -20°C for short and long-term storage, respectively. 577 578

We recombinantly expressed human ACE2-Fc in Expi293 cells using a previously described method with 580 minor modification 62 . Briefly, we transfected the ACE2-Fc expression vector into Expi293T cells (Sigma-Aldrich). Five days after transfection, we centrifuged the cultures at 4°C and 300 g for 5 min and 582 collected the supernatant. We further separated cell debris and supernatant by centrifuging at 10,000 g 583 and 4°C for 20 min. After resuspending it in PBS, we purified ACE2-Fc over Protein A Agarose (Thermo 584

Fisher 15918014). We next equilibrated the Protein A Agarose in PBS buffer, ran through the supernatant 585 three times, and used 10 bed volumes of PBS buffer for washing. Finally, we used 100 mM glycine-HCL 586 at pH 2.4 to elute ACE2-Fc into 0.1x volume Tris buffer at pH 8.5 and 100 mM NaCl. We kept purified 587

ACE2-Fc at 4°C and -20°C for short and long-term storage, respectively. 588 589

Expression and purification of SARS-CoV-2 spike proteins 590 We transfected and expressed plasmids using Expi293 cells using previously described methods 26 . 591

Briefly, we purified variants from 40 mL of cell culture. We filtered the supernatant using a 0.22-μm filter 592

and ran it through a StrepTactin Superflow column (IBA 2-1206-025). We further purified spikes via 593

Superose 6 Increase 10/300 (GE GE29-0915-96) size-exclusion column chromatography with a buffer 594 containing 2 mM Tris at pH 8.0, 200 mM NaCl, and 0.02% NaN3. We kept purified samples at 4°C and -595

20°C for short and long-term storage, respectively. 596 597 HEK293T transfection 598 We seeded cells into 6 or 12-well polystyrene-coated plates (VWR 10861-696, 10861-698) at a density of 599 0.3 x 10 6 cells mL -1 or 0.1 x 10 6 cells mL -1 , respectively, one day before transfection. At 60-80% 600 confluence, we used Lipofectamine 3000 (Thermo Fisher L3000015) and Opti-MEM (Gibco 51985091) 601

to transfect cells with expression plasmids (3 μL of lipofectamine per μg of plasmid DNA) according to 602 manufacturer instructions. At 48 h post-transfection, we assayed or collected the cells. 603 604

At 48 h post-transfection, we collected HEK293T cells containing surface-displayed spike. We washed 606 cells once with PBS and used gentle pipetting to resuspend them in PBS. We used the Logos Biosystems 607 (L40002) cell counter to determine cell density and spun cells down at 200 g for 1 min. We next decanted 608 the supernatant and resuspended cells to a density of ~3 x 10 6 cells mL -1 in chilled PBS-BSA using 1% 609 BSA (Sigma-Aldrich A3294), 1X PBS, and 2 mM EDTA at pH 7.4. 610

We used Axygen deep well grow blocks (P-2ML-SQ-C-S) to prepare flow cytometric assays. We 611 added predetermined concentrations of primary antibody or chimeric cell receptor (ACE2-Fc) diluted in 612 PBS-BSA and 50 μL (1.5 x 10 5 ) of HEK293T cells to each well. We incubated the mixtures at room 613 temperature for 1 h with shaking at 950 rpm. To pellet cells, we spun plates at 500 g in a swinging bucket 614 rotor for 2 min. We then washed cells twice by decanting the supernatant and adding 500 μL of PBS-BSA 615

to each well. To each well, we added 500 μL total volume of 5 μM Alexa Fluor® 488 anti-mouse 616 secondary (SouthernBiotech 1031-30) and 10 μM Alexa Fluor® 647 anti-human secondary 617

(SouthernBiotech 2048-31) antibodies in PBS-BSA. We incubated plates in the dark for 25 min at 4°C 618 with shaking at 950 g. We washed each well twice with PBS-BSA and resuspended cells in PBS-BSA 619

(300 μL) before loading them onto the SA3800 Spectral Cell Analyzer (SONY). 620

To establish forward scatter-area (FSC-A) and side scatter-area (SSC-A) gating, we used 621

HEK293T cells. For singlet discrimination, we gated with forward scatter-height (FSC-H) vs forward 622 scatter-area (FSC-A) and side scatter-height (SSC-H) vs side scatter-area (SSC-A). For each assayed 623 sample, we acquired a minimum of 10,000 singlet events. We further analyzed singlet HEK293T cells 624

using Alexa Fluor 488 (AF-488) and Alexa Fluor 647 (AF-647) channels with excitation and detection 625 settings recommended by the manufacturer. To reduce spectral spill-over and autofluorescence effects, we 626

applied spectral unmixing to all data. 627

For each sample, we measured the median height (H) for the AF-488 and AF-647 channels. To 628 measure spike expression, we used the signal from the AF-488 channel (anti-FLAG). We used the 629 following equation to calculate the expression of spike variant (x) relative to WT (6P-D614G): 630 631 = 2 ( : 488_ / : 488_ 6 _ 614 ) 632 633

To correct for changes in transfection efficiency or spike expression in antibody or ACE2 binding 634 measurements, we also included anti-FLAG signal as an internal normalization control. We used the We used FlowJo v9 for all flow cytometry data analyses. 641 642 

To measure human sera and monoclonal antibody neutralization titers, we used a fluorescent focus 644 reduction neutralization test (FFRNT) with an mNeonGreen (mNG) reporter SARS-CoV-2 (strain USA-645 WA1-2020) or SARS-CoV-2 (strain USA-WA1-2020) bearing a variant spike gene

We incubated plates at 37°C with 5% 649 CO2 overnight. The next day, each sample was two-fold serially diluted in culture medium with an initial 650 dilution of 1:20. We incubated diluted serum or antibody with 100-150 fluorescent focus units (FFU) of 651 mNG SARS-CoV-2 at 37°C for 1 h before loading the serum-virus mixtures into 96-well plates pre-seeded 652 with Vero E6 cells. Following a 1 h infection period, we removed the inoculum and added overlay medium 653 (100 μL DMEM + 0.8% methylcellulose, 2% FBS, and 1% penicillin/streptomycin). We then incubated the 654 plates at 37°C for 16 h and acquired raw images of mNG fluorescent foci using a Cytation TM 7 (BioTek) 655 cell imaging reader with a 2.5× FL Zeiss objective and wide field of view. We used GFP software settings 656 [469,525], a threshold of 4000, and an object selection size of 50-1000 µm during image processing. For 657 relative infectivity calculations, we counted and normalized the foci in each well relative to non-658 serum/antibody-treated controls. We plotted curves of relative infectivity versus serum dilution using

After 3C protease-mediated cleavage, we diluted supernatants containing spike variants two-fold with 666 BLI Kinetics Buffer (Fortébio) containing 10 mM HEPES at pH 7.5, 150 mM NaCl

and 1 mg mL -1 BSA. We also serially diluted analytes with the 668 BLI buffer

For each assay, we performed the following steps: 1) 671 baseline: 60 s with BLI buffer; 2) IgG immobilization: 360 s with anti-FLAG IgG; 3) spike loading: 360 s 672 with diluted supernatants; 4) baseline: 300 s with BLI buffer; 5) association: 600 s with serially diluted 673 analytes (antibodies or ACE2); 6) dissociation: 600 s with BLI buffer. We used Octet Data Analysis 674 software v11

Differential Scanning Fluorimetry

Sample solutions containing 5X SYPRO Orange Protein Gel Stain (Invitrogen S6651) and 0.15-0.20 678 mg/mL of purified spike protein were added to a 96-well qPCR plate

Fluorescence measurements were obtained continuously using λex=465 nm and λem=580 nm

Roche LightCycler 480 II, and a temperature ramp rate of 4.5°C/minute increasing from 22 °C to 95 °C

SARS-CoV-2 spike proteins generate two local minimums that we report to as Tm1 and Tm2. All 683 data were visualized in GraphPad Prism 9. For simplicity, we normalize all melting curve traces by their 684 absolute min -df/dT value

Computational analysis of GISAID sequence data

To investigate the clinical frequency of SARS-CoV-2 spike mutations and the probability of mutation co-688 occurrences, we performed pairwise amino acid sequence alignments between the GISAID spike 689 reference sequence, GenBank number QHR63250.2, and all GISAID EpiCoV database SARS-CoV-2 690 spike amino acid sequences. We downloaded amino acid sequences from GISAID

We performed semi-global amino acid sequence alignment using 692 MATLAB's Needleman-Wunsch alignment function as a part of its Bioinformatics Toolbox add-on. We 693 set alignment parameters to include no gap open penalty at the beginning and end of sequences, an 694 internal gap open penalty of 5, a gap extension penalty of 2, and the BLOSUM80 scoring matrix

We filtered alignment pairs to remove all sequences that were non-human in origin, sequences 697 containing over 1280 or fewer than 1260 amino acids, and sequences containing more than 800 unknown 698

Sequences containing a specific mutation) / Σ(all mutations in all sequences

We found mutations that occurred independently by removing all alignment pairs that did not 704 contain the target mutation and sequences that contained mutations other than the target mutation

Additionally, we considered alignment pairs for which the only other mutation (other than the target) was

D614G were as independent, as D614G was highly prevalent in all strains after its initial appearance. The 707 following equation was used to calculate frequency for independent mutations

Sequences containing only the specified mutation or the specified mutation and 710 D614G) / Σ(number of all sequences searched)

to 0) and 715 converted them to monochromatic ChimeraX color codes representing changes in binding relative to 6P-716 D614G spike. Dark red indicates decreased binding and white indicates no change in binding. For every 717 amino acid screened in our Spike Display assay, we superimposed these colors scales onto spike protein 718 structures. In figures showing grouped antibody epitopes, we averaged normalized binding values for all 719 mutations in each position for every antibody comprising that group

The means ± S.D. log-transformed values, or non-transformed values were calculated and reported for all

The biological and clinical significance of emerging SARS-CoV-2 variants

Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7. Nature 1-9

SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. 748

Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in 750 England

Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation. 752

Tracking SARS-CoV-2 variants

Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant. 755

Relative Reproduction Number of SARS-CoV-2 Omicron (B.1.1.529)

Compared with Delta Variant in South Africa

Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern 759

10. Reuters. WHO says Omicron in 89 countries and spreading rapidly

Rapid spread of SARS-CoV-2 Omicron subvariant BA.2 in a single-source 762 community outbreak

Virological characteristics of SARS-CoV-2 BA.2 variant

Adaptive immunity to SARS-CoV-2 and COVID-19

The T cell immune response against SARS-CoV-2

Divergent SARS-CoV-2 Omicron-reactive T and B cell responses 769 in COVID-19 vaccine recipients

SARS-CoV-2 human T cell epitopes: Adaptive immune response against 771 COVID-19

SARS-CoV-2 variants, spike mutations and immune escape

Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. 775

Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic 777 shift

Considerable escape of SARS-CoV-2 Omicron to antibody neutralization

Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. 781

Antibody evasion properties of SARS-CoV-2 Omicron sublineages

Rapid characterization of spike variants via mammalian cell surface display

Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases 787 Infectivity of the COVID-19 Virus

Molecular Architecture of Early Dissemination and Massive Second Wave of 789 the SARS-CoV-2 Virus in a Major Metropolitan Area

Structure-based design of prefusion-stabilized SARS-CoV-2 spikes

SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. 793

A neutralizing human antibody binds to the N-terminal domain of the Spike protein 795 of SARS-CoV-2

Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal 797 domain target a single supersite

Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-799 RBD spike epitopes

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

Mapping mutations to the SARS-CoV-2 RBD that escape binding by 803 different classes of antibodies

Studies in humanized mice and convalescent humans yield a SARS-CoV-2 805 antibody cocktail

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with 807 Covid-19

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody 811 Sotrovimab

SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape

Synthetic repertoires derived from convalescent COVID-19 patients enable 815 discovery of SARS-CoV-2 neutralizing antibodies and a novel quaternary binding modality

Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants

Neutralization of SARS-CoV-2 Omicron 820 BA.2 by Therapeutic Monoclonal Antibodies

Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 823 variants

SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-827 induced sera

N-terminal domain antigenic mapping reveals a site of vulnerability for 829 SARS-CoV-2

Neutralizing antibody 5-7 defines a distinct site of vulnerability in SARS-CoV-2 831 spike N-terminal domain

Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike 833 Receptor-Binding Domain by Structure-Guided High-Resolution Serology

Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding 836 domain that affect recognition by polyclonal human plasma antibodies

Antibodies elicited by mRNA-1273 vaccination bind more broadly to the 839 receptor binding domain than do those from SARS-CoV-2 infection

Epistasis at the SARS-CoV-2 Receptor-Binding Domain Interface and the 842 Propitiously Boring Implications for Vaccine Escape

Shifting mutational constraints in the SARS-CoV-2 receptor-binding domain 844 during viral evolution

Structural basis of SARS-CoV-2 Omicron immune evasion and receptor 846 engagement

Cryo-EM structure of the SARS-CoV-2 Omicron spike

Structures of the Omicron Spike trimer with ACE2 and an anti-Omicron

Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals 853 Constraints on Folding and ACE2 Binding

SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD 855 in vitro evolution

D614G Mutation Alters SARS-CoV-2 Spike Conformation and Enhances 857

Protease Cleavage at the S1/S2 Junction

Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the 859 Alpha variant B.1.1.7. Cell Rep

Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. 861

Increased risk of SARS-CoV-2 reinfection associated with emergence of 863 Omicron in South Africa. Science 0, eabn4947. 864 60. Stalls, V. et al. Cryo-EM structures of SARS-CoV-2 Omicron BA.2 spike

Development and structural basis of a two-MAb cocktail for treating SARS-CoV-867 2 infections

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation